Open Access<p>Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer</p>
Author(s) -
Zhiduan Cai,
Yulin Deng,
JianHeng Ye,
Yangjia Zhuo,
Zezhen Liu,
Yingke Liang,
Hui Zhang,
Xinwen Zhu,
Yunping Luo,
Yuanfa Feng,
Ren Liu,
Chuan Fei Guo,
Yunxiang Wu,
Zhengxue Han,
YuXiang Liang,
Funeng Jiang,
Weide Zhong
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s255817
Subject(s) - downregulation and upregulation , prostate cancer , cell growth , cancer research , gene knockdown , cell cycle , cell , cancer , biology , prostate , apoptosis , medicine , biochemistry , gene
Citrate synthase (CS) is a rate-limiting enzyme in the citrate cycle and is capable of catalyzing oxaloacetate and acetyl-CoA to citrate. CS has been uncovered to be upregulated in a variety of cancers, and its expression and clinical significance in prostate cancer (PCa) remain unknown.